Project Grant HT94252411018

The National Cancer Institute awarded Emory University a $1,295,039 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to conduct research on improving immune modulation for smoldering myeloma, a precursor state to multiple myeloma. The project aims to evaluate how properties of immune cells in smoldering myeloma correlate with progression to clinical myeloma, examine changes in immune cells during therapy with Iberdomide or Iberdomide plus Dexamethasone, and...

This Project Grant award of $623,120.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate pharmacological degradation of two chromatin-regulating proteins, CBP and P300, as a potential therapeutic strategy for treating multiple myeloma. The key objectives are to: Use CBP/P300 inhibitors and degraders to assess the comparative effects of disrupting these proteins in multiple myeloma cells through epigenomic, transcriptomic, and chromatin...

This federal Project Grant award of $620,521, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports an integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response. The key products and services to be delivered under this 5-year award, which commenced on January 1, 2025, include: Developing a novel hybrid cellular automata mathematical model to describe the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $173,500.00 to Health Research, Inc. to investigate the effects of CXCR1/2 inhibition on the immune microenvironment of patients with multiple myeloma. The primary goal is to characterize the phenotype and transcriptional changes in myeloid cells in the tumor microenvironment of multiple myeloma patients, and to evaluate the efficacy of CXCR2 inhibitors in preclinical models. The...

This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,602,000.00 to The Children's Hospital of Philadelphia Research Institute to develop and optimize a new class of Epigenetic Reprogramming Factors (ERFs) that can target hundreds, thousands, or tens of thousands of DNA regions in a pathway-specific manner. The goal is to leverage this ERF technology to prevent or reverse epigenetic signatures associated...

This federal Project Grant award of $100,760 from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) supports research conducted by the Sloan-Kettering Institute for Cancer Research in New York City. The project aims to engineer biomaterials that can modulate the tumor immune microenvironment, with a focus on developing an innovative RNA interference (RNAi) therapy to inhibit the cancer-promoting factors cyclophilin A and E-selectin in multiple myeloma....

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop novel T-cell imaging techniques to better understand therapy resistance and treatment efficacy of bispecific T-cell engager (BiTE) antibodies targeting B-cell maturation antigen (BCMA) and G protein coupled receptor class C group 5 member D (GPRC5D) in relapsed and refractory multiple myeloma patients. The...

This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $621,156 to The Trustees of the University of Pennsylvania to conduct research aimed at identifying novel regulators of endoplasmic reticulum (ER) homeostasis in malignant plasma cells, with the goal of developing new therapies to target and kill multiple myeloma cells. The 5-year project, starting on January 1, 2025, will leverage experimental systems including a...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop advanced deep learning algorithms to enhance the management of multiple myeloma (MM), a type of hematologic cancer. The $755,336 award, with a period of performance from August 1, 2025 to June 30, 2029, will focus on two key objectives: 1) Developing automated...